Skip to main content
. Author manuscript; available in PMC: 2013 Jul 22.
Published in final edited form as: Endocr Relat Cancer. 2012 Jan 9;19(1):29–38. doi: 10.1530/ERC-11-0155

Figure 2.

Figure 2

Combination therapy in MTC cells. TT (Panels A–C) and MZ-CRC-1 (Panels D–F) cells were treated with each compound alone and in combination with sorafenib (Sor), AZD 6344, and/or everolimus. All potential two-compound combinations were examined and experiments were performed in which each individual compound was kept at a constant concentration or varied. Synergy in both the cell lines was detected only with the combination of sorafenib and AZD6244 (Panels B and E, P<0.001 for both) with the effect being more pronounced for the TT cell line. Data points are estimated means from the mixed-effect model and the error bars are standard error based on residual variance from the mixed-effect model.